Molecular mechanisms of the antitumor effects of anti-CD20 antibodies.
about
Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunityTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyMonoclonal antibodies for the treatment of cancerMechanisms of action of therapeutic antibodies for cancerA phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.Classification of current anticancer immunotherapiesTrial Watch: Monoclonal antibodies in cancer therapyA bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cellsTransient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques.Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapyMultiplexed Fc array for evaluation of antigen-specific antibody effector profiles.Adenanthin, a new inhibitor of thiol-dependent antioxidant enzymes, impairs the effector functions of human natural killer cells.Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement.Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complement-dependent cytotoxicityDetermining the phagocytic activity of clinical antibody samples.Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice.Targeting microglia for the treatment of Alzheimer's Disease.Trial watch: Monoclonal antibodies in cancer therapy
P2860
Q26862220-B921C1D1-CE43-4690-B009-0E5D1AC9E790Q26993238-FB57D509-D34B-4DFA-B2BE-40B0F00392E5Q27025966-0A79483B-2C14-4343-8207-ED7659AB0391Q28385366-BE3E0A82-1827-4927-B7A6-20E12BF28E98Q33626106-2F7B4F5C-91FC-4254-A11D-1926A5F56F95Q35149637-E8A503F5-B517-43B2-82E5-F14C166D4F25Q36038408-EBF85806-261D-4AD0-865D-F213B067AFCEQ36216038-0158336C-B3C4-476E-B945-DF64CBBA4A7AQ36673736-C86B4327-D6F5-4B66-B04A-FB266F66ED52Q37652790-DD4A5C26-BFFB-4BBE-8989-B308D5477F96Q37677278-027E8BD1-0FEE-4E95-8214-BB3CDF731388Q38861743-0B062E24-9C75-4C4D-82B2-6A32BC89B7A9Q39066434-87614454-70A9-481B-848F-3E5AC75D0811Q39306456-62AB9A03-585B-427D-AB4F-B344411AF2B6Q39432766-861676A3-4048-4A00-9379-51E443681BF9Q42558833-ADA48321-CA2A-4366-BAF0-797348B24C98Q51076481-8A9D6209-45CB-4F53-A127-994289EC7C62Q53376999-A9F59EBC-26FE-4698-837C-1A27055CCB83Q56932681-6612633E-ABB5-4BE4-8F67-07486E8B6F3F
P2860
Molecular mechanisms of the antitumor effects of anti-CD20 antibodies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular mechanisms of the antitumor effects of anti-CD20 antibodies.
@en
Molecular mechanisms of the antitumor effects of anti-CD20 antibodies.
@nl
type
label
Molecular mechanisms of the antitumor effects of anti-CD20 antibodies.
@en
Molecular mechanisms of the antitumor effects of anti-CD20 antibodies.
@nl
prefLabel
Molecular mechanisms of the antitumor effects of anti-CD20 antibodies.
@en
Molecular mechanisms of the antitumor effects of anti-CD20 antibodies.
@nl
P50
P356
P1476
Molecular mechanisms of the antitumor effects of anti-CD20 antibodies.
@en
P2093
Magdalena Winiarska
P304
P356
10.2741/3688
P577
2011-01-01T00:00:00Z